Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor Supplementary Figure 2

Chenyue Zhang, Kai Wang, Jiamao Lin & Haiyong Wang
Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor Supplementary Figure 2
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.